Vermillion, Inc. (NASDAQ:VRML) has been assigned an average broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.
Brokers have set a one year consensus price objective of $2.25 for the company, according to Zacks. Zacks has also given Vermillion an industry rank of 84 out of 255 based on the ratings given to its competitors.
Separately, ValuEngine raised shares of Vermillion from a “hold” rating to a “buy” rating in a report on Friday, July 6th.
Vermillion (NASDAQ:VRML) last released its earnings results on Thursday, August 9th. The company reported ($0.04) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). The company had revenue of $0.71 million during the quarter. Vermillion had a negative net margin of 398.14% and a negative return on equity of 201.03%.
In other Vermillion news, CFO Robert Harry Beechey purchased 75,000 shares of the firm’s stock in a transaction dated Thursday, August 23rd. The stock was acquired at an average cost of $0.61 per share, with a total value of $45,750.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Valerie Barber Palmieri purchased 97,000 shares of the firm’s stock in a transaction dated Friday, August 17th. The stock was acquired at an average cost of $0.52 per share, with a total value of $50,440.00. Following the completion of the acquisition, the chief executive officer now directly owns 178,063 shares in the company, valued at approximately $92,592.76. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 291,100 shares of company stock valued at $157,931 and sold 33,473 shares valued at $16,837. Insiders own 4.25% of the company’s stock.
A hedge fund recently bought a new stake in Vermillion stock. Manatuck Hill Partners LLC bought a new stake in shares of Vermillion, Inc. (NASDAQ:VRML) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 379,700 shares of the company’s stock, valued at approximately $296,000. Manatuck Hill Partners LLC owned 0.50% of Vermillion as of its most recent SEC filing. Hedge funds and other institutional investors own 26.70% of the company’s stock.
Vermillion Company Profile
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Read More: Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.